Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

Claire Harrison, MD, reviews the use of ruxolitinib in patients who are ineligible for hydroxycarbamide for the management of polycythemia vera (PV).